title: Venous thromboembolism in patients with glioblastoma multiforme: Findings of the RIETE registry.
abstract: BACKGROUND
  There is uncertainty about the optimal therapy of venous thromboembolism (VTE) in patients with glioblastoma multiforme (GBM).
  
  
  METHODS
  We used the RIETE (Registro Informatizado Enfermedad TromboEmbólica) database to compare the rate of VTE recurrences and major bleeding during the course of anticoagulation in patients with GBM, other cancers and in patients without cancer.
  
  
  RESULTS
  As of September 2014, 53,546 patients have been recruited in RIETE. Of these, 72 (0.13%) had GBM and 11,811 (22%) had other cancers. Most patients in all 3 subgroups received initial therapy with low-molecular-weight heparin (LMWH), but those with GBM received slightly lower doses than those with other cancers or without cancer. Then, most patients with GBM continued on LMWH for long-term therapy, at similar doses than those in the other subgroups. During the course of anticoagulation (mean, 202 days), 3 patients with GBM presented VTE recurrences (10.9 per 100 patient-years; 95% CI: 2.76-29.5) and 4 suffered major bleeding (one intracranial) (14.5 bleeds per 100 patient-years; 95%CI: 4.60-34.9). Compared with patients with other cancers, those with GBM had a similar rate of VTE recurrences and major bleeds, but had a higher rate of extracranial hematoma (p<0.05). Compared with VTE patients without cancer, those with GBM had a higher rate of PE recurrences (p<0.01) and major bleeding (p<0.001), particularly extracranial hematoma (p<0.001).
  
  
  CONCLUSIONS
  Patients with GBM and VTE had a similar rate of VTE recurrences or major bleeds during the course of anticoagulant therapy than those with other cancers.
authors.affiliation: Department of Internal Medicine, Hospital General Universitario de Ciudad Real, Spain; Facultad de Medicina de Ciudad Real, Universidad de Castilla La Mancha, Spain.
authors.forename: Jose
authors.initials: J
authors.lastname: Portillo
authors.affiliation: Department of Internal Medicine, Hospital General Universitario de Ciudad Real, Spain.
authors.forename: Iris Violeta
authors.initials: IV
authors.lastname: de la Rocha
authors.affiliation: Department of Haematology, Hospital de Tortosa Verge de la Cinta, Tarragona, Spain.
authors.forename: Llorenç
authors.initials: L
authors.lastname: Font
authors.affiliation: Department of Haematology, Galilee Medical Center, Nahariya, "Azriel" Faculty of Medicine in Galilee, Bar-ilan University, Israel.
authors.forename: Andrei
authors.initials: A
authors.lastname: Braester
authors.affiliation: Department of Internal Medicine, Hospital Infanta Sofía, Madrid, Spain.
authors.forename: Olga
authors.initials: O
authors.lastname: Madridano
authors.affiliation: Department of Internal Medicine, Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain.
authors.forename: José Antonio Díaz
authors.initials: JA
authors.lastname: Peromingo
authors.affiliation: Department of Angiology, Ospedale Belcolle di Viterbo, Viterbo, Lazio, Italy.
authors.forename: Alessandro
authors.initials: A
authors.lastname: Apollonio
authors.affiliation: Department of Internal Medicine, Hospital de Madrid Norte Sanchinarro, Madrid, Spain.
authors.forename: Barbara
authors.initials: B
authors.lastname: Pagán
authors.affiliation: Department of Internal Medicine, Hospital Infanta Leonor, Madrid, Spain.
authors.forename: José
authors.initials: J
authors.lastname: Bascuñana
authors.affiliation: Department of Internal Medicine, Hospital Universitari Germans Trias i Pujol, Badalona, Universidad Católica de Murcia, Spain. Electronic address: mmonreal.germanstrias@gencat.cat.
authors.forename: Manuel
authors.initials: M
authors.lastname: Monreal
mesh_terms: D000368:Aged; D000925:Anticoagulants / Q000627:therapeutic use; D001932:Brain Neoplasms / Q000150:complications / Q000175:diagnosis; D003625:Data Collection; D016208:Databases, Factual; D005060:Europe; D005260:Female; D005909:Glioblastoma / Q000150:complications*; D006406:Hematoma / Q000150:complications; D006470:Hemorrhage; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use; D006801:Humans; D007391:International Cooperation; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D012042:Registries; D016896:Treatment Outcome; D054556:Venous Thromboembolism / Q000150:complications* / Q000517:prevention & control
chemical_list: D000925:Anticoagulants; D006495:Heparin, Low-Molecular-Weight
keywords: Anticoagulant therapy; Bleeding; Glioblastoma; Recurrences; Venous thromboembolism